(MENAFN- Investor Brand Network)
RYAH Group (CSE: RYAH) , a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced plans for a U.S. clinical study focused on treatment COVID-19. RYAH will be partnering with OMNI Medical Services to perform the U.S.-based clinical study evaluating patients using inhalation of medical cannabis to both treat and prevent the coronavirus. The study, which will run for five years, will involve the use of RYAH's Smart Inhaler devices and will involve up to 11,000 of OMNI's patients across the country. Phase 2 of the study is planned for Q2 2022, with an end date in 2024. The strategic plan also includes presenting gathered data to the FDA as part of the effort for national legalization of cannabis for medical use. “We're excited to be working with OMNI on this thoughtful and timely study on the evaluation of novel preventative and treatment measures related to inflammatory effects from COVID-19,” said RYAH Group CEO Gregory Wagner in the press release.“RYAH is honored to be selected to participate in this important project with OMNI, to be contributing to valuable data aggregation, and to raise our understanding of plant-based inhalation methods on potentially addressing anti-inflammatory effects of COVID-19.”
To view the full press release, visit
About RYAH Group Inc.
RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies, as well as licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. For more information about the company, please visit .
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company's newsroom at
About CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published:
Do you have a questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire (CNW)
Toronto, Ontario
905.674.5977 Office
MENAFN20052022000224011066ID1104246330
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.